When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). Itis the most common genetic heart disease in the US and ...
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy ...
Research using heart cells from squirrels, mice and people identifies an evolutionary mechanism critical for heart muscle function. Research using heart cells from squirrels, mice and people ...
Importantly, the experiments showed that treatment with an experimental small-molecule drug restored the balance of myosin arrangements and normalized the contraction and relaxation of both human and ...
Research using heart cells from squirrels, mice and people identifies an evolutionary mechanism critical for heart muscle function. Gene defect that affects a protein found in the heart muscle ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of ...
Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, announced the dosing of the first patient in the phase 2 CIRRUS-HCM trial of EDG-7500. EDG-7500 is a novel oral, ...
Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the heart and a leading cause of sudden cardiac death in young people and athletes. Scientists have long known that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback